UroGen Pharma Ltd (URGN) — Cash Flow-to-Debt Ratio
UroGen Pharma Ltd (URGN) has a Cash Flow-to-Debt Ratio of -0.09x as of June 2026, meaning its operating cash flow of $-33.01 Million could theoretically repay 0% of its total liabilities ($384.99 Million) in one year. See UroGen Pharma Ltd (URGN) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
UroGen Pharma Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for UroGen Pharma Ltd across 13 annual periods. For the full cash flow conversion analysis, see URGN operating cash flow.
Annual Cash Flow-to-Debt Ratio for UroGen Pharma Ltd (2013–2025)
Year-by-year debt coverage analysis for UroGen Pharma Ltd. Check earnings quality score of UroGen Pharma Ltd to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.53x | $-162.44 Million | $305.93 Million | ▼ -61.6% |
| 2024 | -0.33x | $-96.77 Million | $294.51 Million | ▼ -4.8% |
| 2023 | -0.31x | $-76.38 Million | $243.52 Million | ▲ +19.4% |
| 2022 | -0.39x | $-87.56 Million | $224.98 Million | ▲ +49.0% |
| 2021 | -0.76x | $-84.89 Million | $111.33 Million | ▲ +81.5% |
| 2020 | -4.13x | $-105.89 Million | $25.65 Million | ▼ -28.4% |
| 2019 | -3.22x | $-71.02 Million | $22.09 Million | ▼ -16.0% |
| 2018 | -2.77x | $-37.33 Million | $13.46 Million | ▼ -103.8% |
| 2017 | -1.36x | $-9.57 Million | $7.04 Million | ▼ -319.2% |
| 2016 | 0.62x | $4.19 Million | $6.75 Million | ▲ +119.4% |
| 2015 | -3.21x | $-7.17 Million | $2.24 Million | ▲ +30.6% |
| 2014 | -4.62x | $-4.12 Million | $891.00K | ▲ +12.5% |
| 2013 | -5.28x | $-2.56 Million | $484.00K | — |